Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M293Revenue $M31.3Net Margin (%)-1,343.5Z-Score-6.3
Enterprise Value $M401EPS $-1.3Operating Margin %-1,137.7F-Score1
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-1,344.0Higher ROA y-yN
Price/Book76.510-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales13.35-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yN
Price/Cash Flow6.3y-y EBITDA Growth Rate %0ROA % (ttm)-54.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-304.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M195ROI % (ttm)-57.3Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EXELJean-Marie Eveillard 2014-06-30 Sold Out $3.22 - $3.8
($3.45)
$ 1.53-56%Sold Out0
EXELJean-Marie Eveillard 2014-03-31 Reduce-0.01%$3.38 - $8.24
($6.84)
$ 1.53-78%Reduce -65.91%400,000
EXELJohn Burbank 2013-03-31 Sold Out -0.0019%$4.41 - $5.03
($4.69)
$ 1.53-67%Sold Out0
EXELJohn Burbank 2012-12-31 Buy $4.33 - $5.32
($4.79)
$ 1.53-68%New holding, 10753 sh.10,753
EXELJean-Marie Eveillard 2012-09-30 Add0.02%$4.28 - $6.45
($5.29)
$ 1.53-71%Add 422.58%1,175,800
EXELJean-Marie Eveillard 2012-03-31 Add$4.49 - $6.47
($5.14)
$ 1.53-70%Add 125%225,000
EXELJean-Marie Eveillard 2011-12-31 Buy $3.95 - $7.81
($5.01)
$ 1.53-70%New holding, 100000 sh.100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
($7.34)
$ 1.53-79%Sold Out0
EXELJean-Marie Eveillard 2011-03-31 Sold Out $7.22 - $12.45
($9.89)
$ 1.53-84%Sold Out0
EXELJean-Marie Eveillard 2010-12-31 Buy 0.01%$3.98 - $9.08
($5.66)
$ 1.53-73%New holding, 280000 sh.280,000
EXELJean-Marie Eveillard 2009-12-31 Sold Out -0.02%$5.33 - $8
($6.86)
$ 1.53-78%Sold Out0
EXELJean-Marie Eveillard 2009-09-30 Buy 0.02%$4.4 - $6.99
($5.65)
$ 1.53-73%New holding, 274700 sh.274,700
EXELJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$4.16 - $5.55
($4.88)
$ 1.53-69%Sold Out0
EXELJean-Marie Eveillard 2009-03-31 Reduce$4.32 - $5.85
($4.8)
$ 1.53-68%Reduce -25.67%144,800
EXELCarl Icahn 2008-12-31 Add0.19%$2.4 - $5.12
($3.8)
$ 1.53-60%Add 80.31%2,357,110
EXELJean-Marie Eveillard 2008-12-31 Add$2.4 - $5.12
($3.8)
$ 1.53-60%Add 25.84%194,800
EXELCarl Icahn 2008-09-30 Buy 0.18%$4.8 - $7.12
($6.1)
$ 1.53-75%New holding, 1307280 sh.1,307,280
EXELJean-Marie Eveillard 2008-09-30 Reduce$4.8 - $7.12
($6.1)
$ 1.53-75%Reduce -44.12%154,800
EXELJean-Marie Eveillard 2008-06-30 Add0.01%$5.07 - $7.93
($6.7)
$ 1.53-77%Add 151.82%277,000
EXELGeorge Soros 2008-06-30 Sold Out $5.07 - $7.93
($6.7)
$ 1.53-77%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
EXEL Jean-Marie Eveillard 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARCHESI VINCENT TDirector 2014-09-17Buy20,000$1.71-10.53view
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.15-70.29view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.68-67.31view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.72-67.58view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.39-65.15view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.13-70.18view
RIVERA LUPE MEVP, Operations 2010-12-17Sell29,427$8.5-82view
RIVERA LUPE MEVP, Operations 2010-12-15Sell75,000$7.5-79.6view
Schwab GiselaEVP & Chief Medical Officer 2010-12-09Sell4,112$6.5-76.46view
WILLSEY LANCEDirector 2010-09-07Buy36,200$3.6-57.5view

Press Releases about EXEL :

    Quarterly/Annual Reports about EXEL:

    News about EXEL:

    Articles On GuruFocus.com
    5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
    Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
    Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
    Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
    Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
    Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 
    Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Dec 12 2008 

    More From Other Websites
    Ahead of the Bell: Exelixis shares soar Sep 29 2014
    Ahead of the Bell: Exelixis shares soar Sep 29 2014
    4:01 am Exelixis announces positive results from Phase 3 pivotal trial of Cobimetinib in combination... Sep 29 2014
    Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with... Sep 29 2014
    EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Sep 25 2014
    Why Exelixis (EXEL) Stock Might be a Great Pick Sep 18 2014
    Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress Sep 17 2014
    Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9 Sep 08 2014
    EXELIXIS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Sep 05 2014
    Exelixis Slumps 55% on Disappointing Cabozantinib Results Sep 03 2014
    Exelixis (EXEL) Enters Oversold Territory Sep 03 2014
    Exelixis Plunges On Drug Trial Failure; Investors See Potential Sep 02 2014
    After the Exelixis Implosion, Is There Anything Left Ahead? Sep 02 2014
    Why Exelixis (EXEL) Stock Plunged to a One-Year Low Today Sep 02 2014
    Exelixis Drug Fails Pivotal Prostate Cancer Study Sep 02 2014
    Ahead of the Bell: Exelixis shares tumble Sep 02 2014
    Ahead of the Bell: Exelixis shares tumble Sep 02 2014
    US STOCKS-Wall St set for flat open; manufacturing data on tap Sep 02 2014
    US STOCKS-Wall St set for flat open; manufacturing data on tap Sep 02 2014
    Exelixis downgraded by Stifel Sep 02 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK